Go to main content


Boldness and passion
The path GC Biopharma has taken.

Boldness to Rise to Every New Challenge is Behind
Every Important Turn in GC Biopharma’s History.

GC Biopharma, which has consolidated its leadership of the Korean healthcare market with innumerable records of being first and best, continues to dream up a healthy future for all peoples worldwide. Always open to the voices of patients and rooting for dreams of a healthier, happier future, through unceasing R&D, GC Biopharma continues to produce innovative health solutions.

2010 to Present

  • 2021Greengene F obtains marketing approval in China for a recombinant treatment for hemophilia
  • 2021Hunterase ICV obtains marketing approval in Japan for severe type of hunter syndrome
  • 2020Hunterase obtains marketing approval in China for hunter syndrome
  • 2020Next generation varicella vaccine obtains marketing approval by KFDA
  • 2019First Korean pharmaceutical company to produce over 200 million flu vaccine doses
  • 2018Won the USD 200 million export award
  • 2018Construction of the cell center completed
  • 2018Company name changed to GC Pharma (currently GC Biopharma)
  • 2017Construction completed of GCBT, the first Korean-built biopharmaceutical plant in North America
  • 2017Celebrated the company’s 50th anniversary
  • 2016GCflu quadrivalent (quadrivalent flu vaccine) wins WHO’s PQ
  • 2015Developed GCflu H5N1, the first avian flu vaccination to be developed in Korea
  • 2015Fourth in the world to develop a quadrivalent flu vaccine (GCflu quadrivalent)
  • 2015Commenced construction of a plasma fractionation plant in Canada
    the first-ever biopharmaceutical plant to be established in
    North America by a Korean company
  • 2014Won the USD 100 million export award and the golden tower
    order of industrial service merit
  • 2014First Korean pharmaceutical company to reach exports valued
    at over USD 200 million in total
  • 2014First Korean pharmaceutical company to produce over 100 million flu
    vaccine doses
  • 2013Completed construction of GC Pharma R&D Center, the largest research facility of its kind in Korea
  • 2013Groundbreaking ceremony for the Red Cross blood fractionation plant in Thailand
  • 2012Hunterase developed announced New Vision 2012
  • 2011Shinbaro developed using nature-derived ingredients
  • 2010CEO Huh Il-sup inaugurated as company chairman

2000 ~ 2010

  • 2009Construction completed of the Ochang plant, a plasma fractionation and genetic recombinant manufacturing facility using the latest technology
  • 2009Greenflu introduced against H1N1, protecting Korean public health against a worldwide epidemic
  • 2009Completed construction of the Hwasun plant, the first-ever manufacturing facility dedicated exclusively to vaccine production
  • 2008Fourth in the world to develop a recombinant treatment for hemophilia (Greengene)
  • 2001Acquired Sang-a Pharmaceuticals
  • 2000Established a Urokinase plant in North Korea

Passion and Promise for a Healthier Life

GC Biopharma has been working hard to become more than a pharmaceutical company, and make itself a leader of the healthcare industry that realizes the promise of a healthier, happier life for all, based on respect for life and dedication

1990 ~ 1999

  • 1999Completed construction of company headquarters in Yongin,
  • 1995Established a vaccine plant in Indonesia
  • 1995Established Green Cross China (currently GC China)
  • 1993Second in the world to develop a varicella vaccine (Suduvax)
  • 1992CEO Huh Young-sup inaugurated as company chairman
  • 1990Korea hemophilia foundation established

1980 ~ 1989

  • 1988First in the world to develop a vaccine against hemorrhagic fever with renal syndrome (Hantavax)
  • 1987First in Korea to develop an AIDS diagnostic kit
  • 1984Established Mogam Biotechnology Institute (currently Mogam Institute for Biomedical Research)
  • 1983Third in the world to develop a hepatitis-B vaccine
  • 1982Developed an intravenous immunoglobulin (IVIG)
  • 1982Established Green Cross Lab (currently GC Labs)
  • 1980Completed construction of company headquarters in
    Seocho-dong, Seoul

1960 ~ 1979

  • 1987Initial public offering
  • 1974Produced antihemophilic factor (AHF)
  • 1973First in Korea to produce Urokinase
  • 1971First in Korea to produce plasma derivatives
  • 1971Company name changes to Green Cross Company Limited
  • 1967Established as Sudo Microorganism Medical Supplies Company

GC Biopharma Owes Its Achievements to Its Past as Green Cross

GC Biopharma’s reputation and achievements today did not come about overnight. They can be credited to the passion and dedication of each and every single person who has worked for the company and ensured its growth over the past half century. GC Biopharma has the world’s trust today thanks to the hard work and discipline of everyone, from researchers to sales representatives.

Plasma fractionation plant
copperplate and ashtray

A copperplate presented as a gift by Cutter, an American company,
upon completion of the construction of Korea’s plasma fractionation plant,
and an accompanying memorial ashtray.


Contains newspaper articles about the company and its achievements in a time before the Internet and smartphones.

1st Green Cross
Captain Award and Medal

Green Cross Awards were instituted to award executives and employees who made major
contributions to the company’s growth.

Business plan and experiment logs

A handwritten business plan and handwritten experiment logs.

Employee card

The vivid inscription below the black-and-white photo reads: “Green Cross Family.”


A Urokinase pamphlet used by the company’s sales representatives.


A notepad containing countless ideas and minutes of meetings that have made Green Cross what it is today.

Pay envelope

An envelope that contained wages for employees, and a breakdown of what was paid.


A urinal to gather urine, the raw material for Urokinase, a thrombolytic agent.


GC녹십자는 이메일 수집을 거부합니다

본 웹사이트에 게시된 이메일 주소가 전자우편 수집 프로그램이나
그 밖의 기술적 장치를 이용하여 무단으로 이메일 주소를 수집하는 행위를 거부하며,
이를 위반시 정보통신망 이용촉진 및 정보보호 등에 관한 법률에 의해 형사처벌됨을
유념하시기 바랍니다

게시일: 2003년 9월 1일